START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer
Status:
Not yet recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
This study is being conducted to explore the immunological mechanism of action of
Peptide-coated Conditionally Replicating Adenovirus-1 (PeptiCRAd-1) plus Checkpoint inhibitor
(CPI) therapy in multiple cancer types, as well as to obtain early information on the safety
of this combination therapy.